Maximizing the benefits of using biosimilars in Egypt

Bibliographic Information
Authors: Fasseeh A.N.; Elezbawy B.; El-Fass K.A.; GamaI M.; Seyam A.; Hayek N.; Abdel Rahman N.; Abdelhamid S.; Fasseeh N.; Saad A.S.; Elagamy A.; Mahmoud A.; Sedrak A.S.; Elshazly K.; Eldebeiky M.; Talaat M.; Mohamed N.M.; Abdelaziz R.A.; Refaat R.; Akeel S.; Abaza S.; Kaló Z.
Journal: Journal of Pharmaceutical Policy and Practice
Publisher: BioMed Central Ltd
Publication Date: 11 March 2024
Volume / Issue: Volume 16 / Issue 1
Article No.: 79
ISSN: 20523211
DOI: 10.1186/s40545-023-00581-w
Scopus: View on Scopus
Document Type: Article
Access: All Open Access; Gold Open Access; Green Open Access
Authors and Affiliations
Fasseeh A.N., Syreon Middle East, Alexandria, Egypt, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt; Elezbawy B., Syreon Middle East, Alexandria, Egypt; El-Fass K.A., Syreon Middle East, Alexandria, Egypt; GamaI M., Egyptian Authority for Unified Procurement, Medical Supply and Technology Management, Cairo, Egypt; Seyam A., Universal Health Insurance Authority, Cairo, Egypt; Hayek N., Theodor Bilharz Research Institute, Giza, Egypt; Abdel Rahman N., Health Insurance Organization, Cairo, Egypt; Abdelhamid S., Egyptian Parliament Health Sector, Cairo, Egypt; Fasseeh N., Faculty of Medicine, Alexandria University, Alexandria, Egypt; Saad A.S., Faculty of Medicine, Ain Shams University, Cairo, Egypt; Elagamy A., Egyptian Authority for Unified Procurement, Medical Supply and Technology Management, Cairo, Egypt; Mahmoud A., Health Insurance Organization, Cairo, Egypt; Sedrak A.S., Universal Health Insurance Authority, Cairo, Egypt, Faculty of Medicine, Cairo University, Cairo, Egypt; Elshazly K., Presidential Program for Women’s Health, Cairo, Egypt; Eldebeiky M., Egyptian Authority for Unified Procurement, Medical Supply and Technology Management, Cairo, Egypt; Talaat M., Egyptian Drug Authority, Cairo, Egypt; Mohamed N.M., Universal Health Insurance Authority, Cairo, Egypt; Abdelaziz R.A., Universal Health Insurance Authority, Cairo, Egypt; Refaat R., Egyptian Authority for Unified Procurement, Medical Supply and Technology Management, Cairo, Egypt; Akeel S., Egyptian Authority for Unified Procurement, Medical Supply and Technology Management, Cairo, Egypt; Abaza S., Syreon Middle East, Alexandria, Egypt; Kaló Z., Semmelweis University, Budapest, Hungary, Syreon Research Institute, Budapest, Hungary
Abstract
Background: Biosimilars constitute a pathway for sustainable financing of healthcare systems in the era of expensive biologics. However, such a pathway is not free of challenges. Since the biosimilars market is expanding in Egypt, there is an urgent need for a policy framework to optimize their use and diffusion in the market. We aim to characterize a national framework based on the experiences of other countries and consultation with local experts. Methods: A narrative literature review was conducted to identify biosimilars’ policy elements worldwide. A workshop was organized with experts to discuss the narrative review findings and create consensus on recommendations. Results: The narrative literature review highlighted the need for biosimilar policy actions in four areas: market authorization, pricing, reimbursement, and uptake. Eighteen experts representing the Egyptian healthcare authorities attended the workshop. The most significant conclusions from the workshop included setting the price of the biosimilar at 30–40% less than its originator’s price and establishing financing protocols, in which the more expensive biologics with significant price premiums should be excluded from the formulary. Conclusions: A summarized national framework policy recommendation for biosimilars was created by local experts from the main public healthcare entities in Egypt. These recommendations coincide with the international policies adopted across different countries that aim to improve patient access while sustaining health expenditure. © 2023, The Author(s).
Keywords
Biosimilars; Health policy; Healthcare sustainability; Patient access; Reimbursement; biosimilar agent; Article; biomedical technology assessment; consensus; drug cost; drug regulation; drug utilization; Egypt; health care access; health care financing; human; immunogenicity; marketing authorization; patient attitude; pharmacovigilance; prescribing practice
Citation Information
Scopus Citations: 4
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
